Category: Research

Researchers have found the origin of group 3 and 4 childhood medulloblastoma, which could help develop new treatments for children diagnosed with one of the most common forms of cancerous brain tumour.

New research suggests that ulixertinib may offer one of the first targeted therapies for the most common form of brain tumour in children.

A major phase III clinical trial has found that novel treatment DCVax®-L may prolong the lives of people diagnosed with a new or recurrent glioblastoma.

The second part of our interview with Sigourney Bell, a third-year PHD candidate at the CRUK Cambridge Institute and co-Founder of Black in Cancer.

We spoke with Sigourney Bell, a third-year PHD candidate at the CRUK Cambridge Institute and co-Founder of Black in Cancer, about her experiences as a researcher.

Verbal fluency test to name animals found to identify those with persistent headaches who are more likely to have a brain tumour, and could help GPs decide who needs rapid imaging.

In this blog, Stephen tells us why it is so important to take part in clinical research. He talks us through his experience of volunteering in the Sativex clinical trial (Phase 1) and joining the Involvement Network.

We respond to preliminary overall survival data from phase III clinical trial that suggests DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

Researchers at University College London have discovered that disulfiram, an anti-alcoholism drug, may help to kill glioma cells in children.

New Year, new research grant opportunities as The Charity is returning to traditional research funding after the pandemic pause with our substantial Future Leaders grants.

Scientists have developed a novel cancer therapy that uses an MRI scanner to guide a magnetic seed through the brain to heat and destroy tumours.

We are delighted to announce that you have made a UK trial of Sativex in glioblastomas possible

Research funded by The Brain Tumour Charity has revealed a new way of classifying meningiomas that can more accurately predict how a tumour will behave and help clinicians identify patients who may benefit from more aggressive treatment earlier. Crucially, researchers have also potentially identified the first-ever drug treatment for most-aggressive forms of meningioma.

Modern molecular profiling of medulloblastomas recently highlighted a previously unrecognised treatment benefit in a major international clinical trial.

Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and, in lab studies working with model cell types, successfully reverse its effects to slow cancer cell growth with a targeted drug.

A new MRI technique that enables doctors to better visualise what the brain is doing could identify specific areas of a slow-growing brain tumour that may be becoming more aggressive. New findings by scientists at the Erasmus University in Rotterdam suggest that visualising the whole tumour may be critical to identifying key changes and where patients may need more active treatment.

If we can find a way to interrupt a cancer cell’s ability to keep dividing, we may have a key to stopping tumours growing. Researchers, Dr Wong and Dr Voon ,tells us about the discovery they made into a tumour’s ability to continuously divide.

Research we funded has added value to a clinical trial that started in 2004. Updated scientific techniques showed that some children with a medulloblastoma can safely be spared harmful treatments.

We hear from two clinical psychologists who are helping young people after their brain tumour treatments through our ACT NOW study.

New research shows that stem cells may be primed to activate. This early stage research could lead us to the reason glioblastomas recur so quickly.

The Brian Cross Memorial Trust will fund ‘Future Leader’ Dr Spencer Watson’s three year glioblastoma brain tumour research.

New ‘Tessa Jowell Centre of Excellence’ status recognises delivery of outstanding care and treatment by NHS staff in their efforts to provide above excellent patient care through a difficult time

The Brain Tumour Charity responds to trial suggesting cannabis-based drug could be combined with chemotherapy in recurrent glioblastomas

We are calling on the Prime Minister to protect charity funded research – and we need your help!